Search clinical trials for: Empegfilgrastim

Total 289 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia (AVOID)

Aggressive B Cell Non-Hodgkin Lymphomas at High Risk for R-CHOP-21-induced Neutropenia

Germany, Italy, Spain
Biocad

Completed

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Chemotherapy-induced Neutropenia

Russian Federation
Biocad

Completed

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Chemotherapy-induced Neutropenia

Russian Federation
Moscow Clinical Scientific Center

Recruiting

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations (Def_Special)

Breast Cancer | Solid Tumor | Gastrointestinal Cancer | Gynecological Malignancies | High-Risk Cancer | Myelosuppression

Russian Federation
Biocad

Recruiting

DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs (DEFENDOR)

Patients With Solid Tumours Who Receive Myelosupressive Therapy

Russian Federation
Coherus Biosciences, Inc.
Community Clinical Oncology Research Network, LLC

Unknown

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca (POEM)

Febrile Neutropenia | Non-myeloid Malignancy

United States
Merckle GmbH

Completed

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Ewing Family of Tumors, Rhabdomyosarcoma

Bulgaria, Czech Republic, Hungary, Poland, Russian Federation, Ukraine
Dr. Reddy's Laboratories Limited

Unknown

A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers

Pharmacokinetics

United States
Merckle GmbH

Completed

PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

Pharmacokinetics | Pharmacodynamics

United Kingdom
Green Cross Corporation
Symyoo

Completed

GCPGC in Chemotherapy-induced Neutropenia

Chemotherapy Induced Neutropenia

Korea, Republic of
Kyowa Kirin Co., Ltd.

Completed

Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

Neutropenia

Japan
Amgen

Completed

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma
Wake Forest University Health Sciences
Atrium Health Levine Cancer Institute

Recruiting

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Breast

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Neutropenia

China
Academisch Ziekenhuis Maastricht
ZonMw: The Netherlands Organisation for Health Research and Development

Completed

Various G-CSF Regimens to Prevent Infection During Chemotherapy

Breast Cancer | Febrile Neutropenia | Chemotherapy

Netherlands
Nanogen Pharmaceutical Biotechnology Joint Stock...

Completed

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

Breast Cancer

Vietnam
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients

Neutropenia

China
Sheba Medical Center

Unknown

Lonquek for Autologous Stem Cell Mobilization

Lymphoma | Multiple Myeloma

Israel
Eli Lilly and Company

Completed

A Dose-Escalation Study for Patients With Advanced Cancer

Advanced Cancer

United States
Rabin Medical Center
Tel-Aviv Sourasky Medical Center; Soroka University Medical Center

Unknown

Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

Lymphoma | Neutropenia

Israel
Eli Lilly and Company

Completed

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cancer of Head and Neck

United States
Eli Lilly and Company

Completed

A Study for Participants With Advanced Cancer

Metastatic Cancer | Advanced Cancer

United States
Amgen

Completed

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Breast Cancer | Non-Hodgkin's Lymphoma | Ovarian Cancer | Lung Cancer | Neutropenia
University Hospital, Clermont-Ferrand
Amgen

Terminated

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Solid Malignancies
Dartmouth-Hitchcock Medical Center

Terminated

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Hematologic Malignancies

United States
University Hospital, Clermont-Ferrand
Amgen

Unknown

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5) (MEG-5)

Solid Malignancies

France
Amgen

Completed

Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy

Non-Small Cell Lung Cancer
Hospital Universitario Dr. Jose E. Gonzalez

Completed

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Lymphoma | Myeloma Multiple

Mexico
Fresenius Kabi SwissBioSim GmbH

Completed

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Healthy

Australia
Nanogen Pharmaceutical Biotechnology Joint Stock...

Completed

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Breast Cancer Female

Vietnam
Afﬁliated Hospital of North Sichuan Medical College

Unknown

A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors

Neutropenia

China
Hoffmann-La Roche

Completed

An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma

Colombia, Mexico
Coherus Biosciences, Inc.

Completed

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Healthy

United States
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Completed

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

Malignant Solid Tumors
Coherus Biosciences, Inc.

Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Bioequivalence

United States
Fresenius Kabi SwissBioSim GmbH

Completed

Safety and Immunogenicity of MSB11455 in Healthy Participants

Healthy

New Zealand
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic/Pharmacodynamic (PK/PD) Study Evaluating Pegfilgrastim Hospira Compared to Neulasta (Amgen) in Healthy Volunteers

Healthy

United Kingdom
EVIVE Biotechnology

Completed

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Breast Cancer | Neutropenia

United States
Qilu Pharmaceutical Co., Ltd.

Unknown

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

Healthy

Germany, United Kingdom
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Completed

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

Breast Cancer
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Completed

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

Lymphoma
Kyowa Kirin Co., Ltd.

Completed

KRN125 for Mobilization of Hematopoietic Stem Cells

Peripheral Blood Stem Cell Transplantation

Japan
Coherus Biosciences, Inc.

Completed

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Immunity, Humoral

United States
Amgen

Completed

Treatment for Elderly Patients With High Risk Breast Cancer

Breast Cancer
Gedeon Richter Plc.

Completed

Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta

Bioequivalence

United Kingdom
University Hospital Tuebingen

Completed

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Non-Hodgkin Lymphoma

Germany
Amgen

Completed

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Neutropenia
M.D. Anderson Cancer Center
Amgen

Completed

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Multiple Myeloma

United States
Buddhist Tzu Chi General Hospital

Recruiting

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Traumatic Optic Neuropathy

Taiwan
Amgen

Completed

Pegfilgrastim PBPC Mobilization Study

Lymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Oncology | Hematology

3

Subscribe